288 related articles for article (PubMed ID: 35634306)
1. CD20
Wu Z; Zhou J; Xiao Y; Ming J; Zhou J; Dong F; Zhou X; Xu Z; Zhao X; Lei P; Huang T
Front Immunol; 2022; 13():865596. PubMed ID: 35634306
[TBL] [Abstract][Full Text] [Related]
2. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
[TBL] [Abstract][Full Text] [Related]
3. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
4. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
Liu Z; Meng X; Tang X; Zou W; He Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
[TBL] [Abstract][Full Text] [Related]
6. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
[TBL] [Abstract][Full Text] [Related]
7. B cells and tertiary lymphoid structures promote immunotherapy response.
Helmink BA; Reddy SM; Gao J; Zhang S; Basar R; Thakur R; Yizhak K; Sade-Feldman M; Blando J; Han G; Gopalakrishnan V; Xi Y; Zhao H; Amaria RN; Tawbi HA; Cogdill AP; Liu W; LeBleu VS; Kugeratski FG; Patel S; Davies MA; Hwu P; Lee JE; Gershenwald JE; Lucci A; Arora R; Woodman S; Keung EZ; Gaudreau PO; Reuben A; Spencer CN; Burton EM; Haydu LE; Lazar AJ; Zapassodi R; Hudgens CW; Ledesma DA; Ong S; Bailey M; Warren S; Rao D; Krijgsman O; Rozeman EA; Peeper D; Blank CU; Schumacher TN; Butterfield LH; Zelazowska MA; McBride KM; Kalluri R; Allison J; Petitprez F; Fridman WH; Sautès-Fridman C; Hacohen N; Rezvani K; Sharma P; Tetzlaff MT; Wang L; Wargo JA
Nature; 2020 Jan; 577(7791):549-555. PubMed ID: 31942075
[TBL] [Abstract][Full Text] [Related]
8. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
Front Immunol; 2022; 13():794217. PubMed ID: 35173719
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
[TBL] [Abstract][Full Text] [Related]
11. Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.
Liang H; Zhang Z; Guan Z; Zheng S; Lou J; Liu W; Cai Q; Si Y
Front Immunol; 2023; 14():1096220. PubMed ID: 36776859
[TBL] [Abstract][Full Text] [Related]
12. [Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer].
Liu Y; Xiong L; Cai R; Chen Y; Ye J; Shen B; Zhou G
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):615-620. PubMed ID: 37752541
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
15. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Kasikova L; Rakova J; Hensler M; Lanickova T; Tomankova J; Pasulka J; Drozenova J; Mojzisova K; Fialova A; Vosahlikova S; Laco J; Ryska A; Dundr P; Kocian R; Brtnicky T; Skapa P; Capkova L; Kovar M; Prochazka J; Praznovec I; Koblizek V; Taskova A; Tanaka H; Lischke R; Mendez FC; Vachtenheim J; Heinzelmann-Schwarz V; Jacob F; McNeish IA; Halaska MJ; Rob L; Cibula D; Orsulic S; Galluzzi L; Spisek R; Fucikova J
Nat Commun; 2024 Mar; 15(1):2528. PubMed ID: 38514660
[TBL] [Abstract][Full Text] [Related]
16. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
Li X; Wan Z; Liu X; Ou K; Yang L
Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
[TBL] [Abstract][Full Text] [Related]
17. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer.
Qin M; Hamanishi J; Ukita M; Yamanoi K; Takamatsu S; Abiko K; Murakami R; Miyamoto T; Suzuki H; Ueda A; Hosoe Y; Horie A; Yamaguchi K; Mandai M
Cancer Immunol Immunother; 2022 Jun; 71(6):1431-1442. PubMed ID: 34689225
[TBL] [Abstract][Full Text] [Related]
19. Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers.
Vanhersecke L; Bougouin A; Crombé A; Brunet M; Sofeu C; Parrens M; Pierron H; Bonhomme B; Lembege N; Rey C; Velasco V; Soubeyran I; Begueret H; Bessede A; Bellera C; Scoazec JY; Italiano A; Fridman CS; Fridman WH; Le Loarer F
Lab Invest; 2023 May; 103(5):100063. PubMed ID: 36801637
[TBL] [Abstract][Full Text] [Related]
20. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]